Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

Elaine M. Hurt, Adrian Wiestner, Andreas Rosenwald, A. L. Shaffer, Elias Campo, Tom Grogan, Peter Leif Bergsagel, W. Michael Kuehl, Louis M. Staudt

Research output: Contribution to journalArticle

262 Citations (Scopus)

Abstract

The oncogene c-maf is translocated in ~5%-10% of multiple myelomas. Unexpectedly, we observed c-maf expression in myeloma cell lines lacking c-maf translocations and in 50% of multiple myeloma bone marrow samples. By gene expression profiling, we identified three c-maf target genes: cyclin D2, integrin β7, and CCR1. c-maf transactivated the cyclin D2 promoter and enhanced myeloma proliferation, whereas dominant inhibition of c-maf blocked tumor formation in immunodeficient mice. c-maf-driven expression of integrin β7 enhanced myeloma adhesion to bone marrow stroma and increased production of VEGF. We propose that c-maf transforms plasma cells by stimulating cell cycle progression and by altering bone marrow stromal interactions. The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)191-199
Number of pages9
JournalCancer Cell
Volume5
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Multiple Myeloma
Cyclin D2
Bone Marrow
Integrins
Gene Expression Profiling
Plasma Cells
Oncogenes
Vascular Endothelial Growth Factor A
Cell Cycle
Cell Line
Genes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. / Hurt, Elaine M.; Wiestner, Adrian; Rosenwald, Andreas; Shaffer, A. L.; Campo, Elias; Grogan, Tom; Bergsagel, Peter Leif; Kuehl, W. Michael; Staudt, Louis M.

In: Cancer Cell, Vol. 5, No. 2, 02.2004, p. 191-199.

Research output: Contribution to journalArticle

Hurt, Elaine M. ; Wiestner, Adrian ; Rosenwald, Andreas ; Shaffer, A. L. ; Campo, Elias ; Grogan, Tom ; Bergsagel, Peter Leif ; Kuehl, W. Michael ; Staudt, Louis M. / Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. In: Cancer Cell. 2004 ; Vol. 5, No. 2. pp. 191-199.
@article{1fd8e627d5b14e99b010d151ff1f8043,
title = "Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma",
abstract = "The oncogene c-maf is translocated in ~5{\%}-10{\%} of multiple myelomas. Unexpectedly, we observed c-maf expression in myeloma cell lines lacking c-maf translocations and in 50{\%} of multiple myeloma bone marrow samples. By gene expression profiling, we identified three c-maf target genes: cyclin D2, integrin β7, and CCR1. c-maf transactivated the cyclin D2 promoter and enhanced myeloma proliferation, whereas dominant inhibition of c-maf blocked tumor formation in immunodeficient mice. c-maf-driven expression of integrin β7 enhanced myeloma adhesion to bone marrow stroma and increased production of VEGF. We propose that c-maf transforms plasma cells by stimulating cell cycle progression and by altering bone marrow stromal interactions. The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention.",
author = "Hurt, {Elaine M.} and Adrian Wiestner and Andreas Rosenwald and Shaffer, {A. L.} and Elias Campo and Tom Grogan and Bergsagel, {Peter Leif} and Kuehl, {W. Michael} and Staudt, {Louis M.}",
year = "2004",
month = "2",
doi = "10.1016/S1535-6108(04)00019-4",
language = "English (US)",
volume = "5",
pages = "191--199",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

AU - Hurt, Elaine M.

AU - Wiestner, Adrian

AU - Rosenwald, Andreas

AU - Shaffer, A. L.

AU - Campo, Elias

AU - Grogan, Tom

AU - Bergsagel, Peter Leif

AU - Kuehl, W. Michael

AU - Staudt, Louis M.

PY - 2004/2

Y1 - 2004/2

N2 - The oncogene c-maf is translocated in ~5%-10% of multiple myelomas. Unexpectedly, we observed c-maf expression in myeloma cell lines lacking c-maf translocations and in 50% of multiple myeloma bone marrow samples. By gene expression profiling, we identified three c-maf target genes: cyclin D2, integrin β7, and CCR1. c-maf transactivated the cyclin D2 promoter and enhanced myeloma proliferation, whereas dominant inhibition of c-maf blocked tumor formation in immunodeficient mice. c-maf-driven expression of integrin β7 enhanced myeloma adhesion to bone marrow stroma and increased production of VEGF. We propose that c-maf transforms plasma cells by stimulating cell cycle progression and by altering bone marrow stromal interactions. The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention.

AB - The oncogene c-maf is translocated in ~5%-10% of multiple myelomas. Unexpectedly, we observed c-maf expression in myeloma cell lines lacking c-maf translocations and in 50% of multiple myeloma bone marrow samples. By gene expression profiling, we identified three c-maf target genes: cyclin D2, integrin β7, and CCR1. c-maf transactivated the cyclin D2 promoter and enhanced myeloma proliferation, whereas dominant inhibition of c-maf blocked tumor formation in immunodeficient mice. c-maf-driven expression of integrin β7 enhanced myeloma adhesion to bone marrow stroma and increased production of VEGF. We propose that c-maf transforms plasma cells by stimulating cell cycle progression and by altering bone marrow stromal interactions. The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=1442285889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442285889&partnerID=8YFLogxK

U2 - 10.1016/S1535-6108(04)00019-4

DO - 10.1016/S1535-6108(04)00019-4

M3 - Article

C2 - 14998494

AN - SCOPUS:1442285889

VL - 5

SP - 191

EP - 199

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -